title: Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.
abstract: A retrospective study was performed to evaluate the outcome of alendronate (ALN) treatment for seven years in postmenopausal Japanese women with osteoporosis. Forty-seven postmenopausal women with osteoporosis (mean age at baseline 65.7 years) treated with ALN for over seven years in our outpatient clinic were analyzed. Lumbar spine bone mineral density (BMD) was measured using dual energy X-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum alkaline phosphatase (ALP) were monitored during the seven-year treatment period. Urinary NTX and serum ALP levels decreased (-48.2% at three months and -15.7% at seven years, respectively) and lumbar spine BMD increased (+12.8% at seven years) compared with baseline values. No serious adverse events were observed, including osteonecrosis of jaw, atypical femoral diaphysis fractures, or atrial fibrillation. To our knowledge, this is the first report of the outcome of ALN treatment for seven years in Japanese patients with osteoporosis. ALN successfully suppressed bone turnover and increased lumbar spine BMD from the baseline value over the course of the seven-year treatment period without causing any severe adverse events.
authors.affiliation: Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Iwamoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Sato
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Uzawa
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takeda
authors.forename: Hideo
authors.initials: H
authors.lastname: Matsumoto
references.citation: N Engl J Med. 2008 Mar 20;358(12):1304-6
references.pmid: 18354114
references.citation: J Bone Miner Metab. 2005;23(3):238-42
references.pmid: 15838627
references.citation: Expert Opin Pharmacother. 2009 Oct;10(14):2303-15
references.pmid: 19640210
references.citation: JAMA. 2006 Dec 27;296(24):2927-38
references.pmid: 17190893
references.citation: J Bone Miner Metab. 2004;22(5):462-8
references.pmid: 15316867
references.citation: J Bone Miner Metab. 2005;23(5):382-8
references.pmid: 16133688
references.citation: Ther Clin Risk Manag. 2009;5:773-9
references.pmid: 19851524
references.citation: Osteoporos Int. 1999;10(3):183-92
references.pmid: 10525709
references.citation: Arch Intern Med. 2008 Apr 28;168(8):826-31
references.pmid: 18443257
references.citation: Bone. 2003 Sep;33(3):301-7
references.pmid: 13678770
references.citation: J Bone Miner Metab. 2005;23(2):97-104
references.pmid: 15750686
references.citation: JAMA. 1998 Dec 23-30;280(24):2077-82
references.pmid: 9875874
references.citation: J Bone Miner Res. 2010 May;25(5):976-82
references.pmid: 20200926
references.citation: Clin Ther. 1999 Jun;21(6):1025-44
references.pmid: 10440625
references.citation: J Bone Miner Metab. 2001;19(6):331-7
references.pmid: 11685647
references.citation: Ann Intern Med. 1999 Dec 21;131(12):935-42
references.pmid: 10610644
references.citation: Osteoporos Int. 2009 Aug;20(8):1429-37
references.pmid: 19101754
references.citation: N Engl J Med. 2007 May 3;356(18):1809-22
references.pmid: 17476007
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155
references.pmid: 18253985
references.citation: N Engl J Med. 2004 Mar 18;350(12):1189-99
references.pmid: 15028823
references.citation: Am J Med. 1997 Oct;103(4):291-7
references.pmid: 9382121
references.citation: Lancet. 1996 Dec 7;348(9041):1535-41
references.pmid: 8950879
references.citation: J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12
references.pmid: 19371809
references.citation: J Bone Miner Res. 2009 Jul;24(7):1308-13
references.pmid: 19257818